Manidipino Stada (Manidipine Dihydrochloride)

Manidipine blocks L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium entry that is necessary for muscle contraction. This inhibition causes vasodilation, reduces peripheral resistance, and consequently lowers arterial blood pressure.

The appropriate dose of Manidipino is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any co‑existing medical issues. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of manidipine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Manidipino, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Manidipino belongs to the dihydropyridine class of calcium channel blockers, offering potent vasodilation with a relatively favorable side‑effect profile compared with non‑selective agents. Compared with ACE inhibitors or ARBs, it primarily reduces peripheral resistance rather than affecting the renin‑angiotensin system, making it useful in patients who cannot tolerate those classes.

Manidipino tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in humid environments or expose the product to extreme temperatures.

Manidipino is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe hypotension, which can cause dizziness, fainting, or shock, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden weakness, swelling of the face or throat, or any signs of a severe allergic response.

Manidipino is contraindicated in patients with known hypersensitivity to manidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis or uncontrolled heart failure unless a specialist determines that benefits outweigh risks.